McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, DAPA HF Committees and Investigators 2019 A trial to evaluate the effect of the sodium glucose co transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction DAPA HF
stromectol for humans 9 1000, venous thromboembolism VTE, and breast cancer with the use of hormone replacement therapy